Overture Life, which said it's behind the world's first babies born from robotic fertilization and robotic egg freezing, today announced the opening of its Dallas facility.
The site will run non-invasive, CLIA-licensed embryo-assessment testing that analyzes molecules in the fluid surrounding embryos (metabolomics) with machine-learning support, giving fertility teams objective data to inform embryo selection without a biopsy. It will also serve as Overture's U.S. clinical operations headquarters.
The Dallas facility is Overture's first dedicated U.S. laboratory, positioning the company to accelerate deployment of its automated IVF platforms that currently operate in clinics across Brazil, Argentina, Chile, Bolivia, Panama, Turkey, and New Jersey.
The Old East Dallas site, near Uptown, will anchor Overture's U.S. expansion as demand builds for its DaVitri automated egg-freezing system. The platform freezes eggs with robotic precision, achieving a 12% improvement in egg survival rates while allowing clinics to process three times the number of procedures without adding staff.
Overture's ICSI.A system achieved the world's first babies born from robotic sperm injection in 2024. Its DaVitri platform standardizes the egg freezing process that typically requires years of specialized training. Together, these systems help laboratories deliver consistent results while reducing the physical strain on embryologists who perform thousands of precise manual procedures annually.
Overture will be hiring for positions across product development, clinical operations, laboratory operations, manufacturing, quality assurance, regulatory affairs, and commercial functions at the Dallas facility. The site will also coordinate with Overture's research and development operations in Spain and its growing network of clinical partners.
The Dallas laboratory joins Overture facilities in Spain as the company builds infrastructure to meet growing demand.
